Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Expenditures (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Capital Expenditures for 11 consecutive years, with $29000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 323.08% to $29000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $252000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $252000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures hit $29000.0 in Q4 2025 for Seres Therapeutics, up from $8000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $9.2 million in Q4 2021 to a low of -$4.1 million in Q3 2022.
  • Historically, Capital Expenditures has averaged $1.0 million across 5 years, with a median of $31500.0 in 2025.
  • Biggest five-year swings in Capital Expenditures: soared 3992.92% in 2021 and later crashed 1297.24% in 2022.
  • Year by year, Capital Expenditures stood at $9.2 million in 2021, then crashed by 86.86% to $1.2 million in 2022, then soared by 525.93% to $7.6 million in 2023, then crashed by 100.17% to -$13000.0 in 2024, then surged by 323.08% to $29000.0 in 2025.
  • Business Quant data shows Capital Expenditures for MCRB at $29000.0 in Q4 2025, $8000.0 in Q3 2025, and $181000.0 in Q2 2025.